- Home
- VTYX vs ACHV Comparison
VTYX vs ACHV Comparison
Compare VTYX & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VTYX
- ACHV
- Stock Information
- Founded
- VTYX 2018
- ACHV N/A
- Country
- VTYX United States
- ACHV United States
- Employees
- VTYX N/A
- ACHV N/A
- Industry
- VTYX Medicinal Chemicals and Botanical Products
- ACHV Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- VTYX Health Care
- ACHV Health Care
- Exchange
- VTYX Nasdaq
- ACHV Nasdaq
- Market Cap
- VTYX 154.9M
- ACHV 167.6M
- IPO Year
- VTYX 2021
- ACHV N/A
- Fundamental
- Price
- VTYX $8.09
- ACHV $4.81
- Analyst Decision
- VTYX Buy
- ACHV Strong Buy
- Analyst Count
- VTYX 3
- ACHV 1
- Target Price
- VTYX $12.50
- ACHV $12.00
- AVG Volume (30 Days)
- VTYX 9.8M
- ACHV 2.4M
- Earning Date
- VTYX 11-06-2025
- ACHV 11-06-2025
- Dividend Yield
- VTYX N/A
- ACHV N/A
- EPS Growth
- VTYX N/A
- ACHV N/A
- EPS
- VTYX N/A
- ACHV N/A
- Revenue
- VTYX N/A
- ACHV N/A
- Revenue This Year
- VTYX N/A
- ACHV N/A
- Revenue Next Year
- VTYX N/A
- ACHV N/A
- P/E Ratio
- VTYX N/A
- ACHV N/A
- Revenue Growth
- VTYX N/A
- ACHV N/A
- 52 Week Low
- VTYX $0.78
- ACHV $1.84
- 52 Week High
- VTYX $9.50
- ACHV $5.78
- Technical
- Relative Strength Index (RSI)
- VTYX 76.14
- ACHV 61.90
- Support Level
- VTYX $5.75
- ACHV $4.65
- Resistance Level
- VTYX $9.50
- ACHV $5.42
- Average True Range (ATR)
- VTYX 0.78
- ACHV 0.44
- MACD
- VTYX 0.33
- ACHV 0.02
- Stochastic Oscillator
- VTYX 76.85
- ACHV 64.34
About VTYX Ventyx Biosciences Inc.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.
About ACHV Achieve Life Sciences Inc.
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.